Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

NCT04912427 | Terminated Phase 1 DMC FDA Drug

• 1 other identifier: 202107134
• Study Type: interventional
• Target: 1
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase Ib study to assess the safety, tolerability, preliminary efficacy, and renal response of isatuximab, bortezomib, and dexamethasone in newly diagnosed multiple myeloma patients with severe renal impairment or dialysis-dependent end-stage renal disease. Such patients have limited therapeutic options due to renal clearance or nephrotoxicity of many myeloma therapies and are often excluded from clinical trials. Isatuximab in other regimens has shown efficacy and tolerability in patients with moderate renal impairment, although data are lacking for regimens containing CD38-targeting immunotherapies in severe renal impairment/ESRD.

Conditions

Multiple Myeloma

Outcome Measures

Primary Outcomes (1)

• Safety and tolerability of the regimen as measured by the proportion of patients that discontinue therapy before Cycle 3 for toxicity or intolerance

  -Patients who discontinue therapy due to COVID-19 will not be included in the calculation of this proportion and will be replaced. Patients who discontinue therapy due to progressive disease before initiation of Cycle 3 will be replaced in the trial.

  Through completion of cycle 3 for all enrolled patients (estimated to be 39 months)

Secondary Outcomes (10)

• Renal response per IMWG criteria

  Through completion of treatment (estimated to be 6 months)

• Overall response rate (ORR) per IMWG criteria

  Through completion of treatment (estimated to be 6 months)

• Progression-free survival (PFS)

  From cycle 1 day 1 through 5 years after completion of treatment (estimated to be 5 years and 6 months)

• Overall survival (OS)

  From cycle 1 day 1 through 5 years after completion of treatment (estimated to be 5 years and 6 months)

• Duration of response (DOR)

  Through completion of treatment (estimated to be 6 months)

Study Arms (1)

Isatuximab + Boretezomib + Dexamethasone

EXPERIMENTAL

* Each cycle is 28 days * Cycle 1 * Days 1, 8, 15, and 22: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time * Cycles 2-8 * Days 1 and 15: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time * Days 8 and 22: Dexamethasone at start time and Bortezomib at 30 minutes after start time * Cycles 9+ * Days 1 and 15: Dexamethasone at start time and Isatuximab at 30-60 minutes after start time

Drug: Isatuximab; Drug: Bortezomib; Drug: Dexamethasone

Interventions

Isatuximab DRUG

Isatuximab is supplied by Sanofi.

Also known as: Sarclisa

Isatuximab + Boretezomib + Dexamethasone

Bortezomib DRUG

Bortezomib is commercially available.

Also known as: Velcade

Isatuximab + Boretezomib + Dexamethasone

Dexamethasone DRUG

Dexamethasone is commercially available.

Isatuximab + Boretezomib + Dexamethasone

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• This study will enroll 28 evaluable patients. Fourteen (+/- 2) patients will be required tto be on dialysis and 14 (+/- 2) patients will not be on dialysis.
• Newly diagnosed multiple myeloma diagnosis according to IMWG criteria. Patients eligible for autologous stem cell transplant may be enrolled if the intent is to proceed to transplant after 4 or more cycles of study treatment.
• Severe renal impairment (eGFR \< 30ml/min/1.73m\^2 using the MDRD calculator) or on dialysis. The value at screening confirms eligibility (if eGFR improves prior to enrollment, this does not render a patient ineligible) The renal impairment may be acute or chronic and may be related to the underlying myeloma (e.g. multiple myeloma (MM) cast nephropathy, monoclonal immunoglobulin deposition disease \[MIDD\], myeloma cell infiltration) or another cause (e.g. diabetes, hypertension), however the acuity/chronicity and the underlying cause should be documented clearly. Those who have acute kidney injury from hypercalcemia should receive intravenous hydration and calcium-lowering therapy to see if this renal impairment is reversible.
• At least 18 years of age.
• ECOG performance status ≤ 2
• Bone marrow and organ function as defined below:
• Absolute neutrophil count ≥ 1,000/mm3 (growth factor to achieve this level is permissible)
• Platelets ≥ 50,000/mm3 (transfusion to achieve this level is permissible)
• Bilirubin ≤ 2 mg/dL
• AST(SGOT)/ALT(SGPT) ≤ 3.5 x institutional upper limit of normal (IULN)
• The effects of isatuximab and bortezomib on the developing human fetus are unknown. For this reason, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 5 months after discontinuation of study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 5 months after completion of the study
• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

You may not qualify if:

• Concomitant use of other anti-neoplastic medications or radiotherapy (except for localized disease). Note: Participants are permitted to have received one dose of bortezomib or up to 80 mg of dexamethasone (or equivalent) prior to study treatment initiation if deemed clinically necessary for disease control.
• Currently receiving any other investigational agents.
• Evidence of myeloma within the CNS
• Presence of amyloidosis without concomitant multiple myeloma. Patients with concomitant amyloidosis and multiple myeloma are eligible.
• Prior refractoriness, intolerance or hypersensitivity to bortezomib.
• Prior treatment with an anti-CD38 monoclonal antibody.
• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to isatuximab, bortezomib, or dexamethasone or other agents used in the study.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
• Active acute or chronic hepatitis B viral infection.
• Screening with serological tests for HBV with surface antigen and antibody (HBsAg and HBsAb) and HBV total core antibody (HBcAb IgG and IgM), and screening for HCV (HCV Ab and HCV RNA level) are required to have been performed within 1 year of screening, or should otherwise be performed as part of screening.
• Patients with uncontrolled or active HBV infection (patients with positive HBsAg and/or HBV DNA), as well as patients with active HCV infection (positive HCV RNA and negative anti-HCV) are not eligible
• In case HBcAb are positive, HBV DNA testing by polymerase chain reaction will also be done at baseline. For patients with positive anti-HBc IgG, negative HBsAg and undetectable (under limit of quantification) HBV DNA at study entry (HBV carriers: past resolved infection, resolving acute infection or receiving antiviral treatment with controlled infection), specialist advice may be requested, close monitoring of viral reactivation throughout and following the end of study treatment should be proposed (alanine aminotransferase, aspartate aminotransferase, and HBV DNA at least every 3 months, up to 6 months after treatment discontinuation or initiation of further anticancer therapy.
• Patients with HIV are eligible unless their CD4+ T-cell counts are \< 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.
• Baseline Grade 2 or higher peripheral neuropathy

Sponsors & Collaborators

• Washington University School of Medicine: lead
• Sanofi: collaborator

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

Related Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

MeSH Terms

Conditions

Multiple Myeloma

Interventions

isatuximab; Bortezomib; Dexamethasone

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Boronic Acids; Acids, Noncarboxylic; Acids; Inorganic Chemicals; Boron Compounds; Organic Chemicals; Pyrazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pregnadienetriols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated

Study Officials

• Keith Stockerl-Goldstein, M.D.

  Washington University School of Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 27, 2021
• First Posted: June 3, 2021
• Study Start: April 1, 2022
• Primary Completion: December 6, 2022
• Study Completion: January 26, 2024
• Last Updated: February 9, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)